Symbols / BCAX Stock $22.65 -0.83% Bicara Therapeutics Inc.
BCAX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Ratings
Current target
$22.65
Low
$16.00
High
$48.00
Mean
$30.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-31 | main | Goldman Sachs | Neutral → Neutral | $16 |
| 2026-03-31 | reit | Wedbush | Outperform → Outperform | $30 |
| 2026-03-31 | main | Wells Fargo | Equal-Weight → Equal-Weight | $16 |
| 2026-03-31 | reit | Citizens | Market Outperform → Market Outperform | $31 |
| 2026-03-31 | main | HC Wainwright & Co. | Buy → Buy | $42 |
| 2026-03-25 | init | B of A Securities | — → Buy | $35 |
| 2026-01-29 | init | Citizens | — → Market Outperform | $31 |
| 2026-01-13 | reit | Wedbush | Outperform → Outperform | $30 |
| 2026-01-08 | init | BTIG | — → Buy | $28 |
| 2025-12-18 | init | Mizuho | — → Neutral | $18 |
| 2025-11-11 | main | Wells Fargo | Equal-Weight → Equal-Weight | $11 |
| 2025-08-22 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-08-19 | init | Piper Sandler | — → Overweight | $36 |
| 2025-05-23 | up | Wells Fargo | Underweight → Equal-Weight | $8 |
| 2025-05-16 | main | HC Wainwright & Co. | Buy → Buy | $41 |
| 2025-04-17 | init | Wells Fargo | — → Underweight | $8 |
| 2025-04-07 | main | HC Wainwright & Co. | Buy → Buy | $44 |
| 2025-03-13 | reit | Cantor Fitzgerald | Overweight → Overweight | $13 |
| 2025-02-12 | reit | Wedbush | Outperform → Outperform | $31 |
| 2025-02-06 | init | Wedbush | — → Outperform | $31 |
- Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN Mon, 27 Apr 2026 00
- [Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan Wed, 22 Apr 2026 20
- Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock - MarketBeat Wed, 22 Apr 2026 21
- Insider Sale: Chief Executive Officer of $BCAX Sells 15,000 Shares - Quiver Quantitative Mon, 20 Apr 2026 23
- BCAX (Bicara Therapeutics Inc.) posts narrow Q4 2025 EPS beat, shares tick higher following its quarterly earnings announcement. - Social Momentum Signals - UBND thành phố Hải Phòng hu, 23 Apr 2026 11
- A Look At Bicara Therapeutics (BCAX) Valuation After Analyst Upgrades And Clinical Progress News - simplywall.st Sun, 05 Apr 2026 07
- BCAX Bicara matches Q4 2025 loss estimates, shares drop 2.25% on lack of revenue progress. - Buyback Report - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 20
- Bicara Therapeutics CFO Hyep sells $211k in stock - Investing.com Wed, 22 Apr 2026 22
- BCAX (BCAX) Form 144 shows option exercise and multiple insider sales - Stock Titan ue, 21 Apr 2026 20
- Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares - MarketBeat ue, 21 Apr 2026 01
- $BCAX stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 08
- New Bicara hire gets stock option for 44,175 shares at $20.50 - Stock Titan Fri, 03 Apr 2026 07
- Bicara Therapeutics (BCAX) CEO sells 15K shares, exercises 37,760 options - Stock Titan Mon, 20 Apr 2026 23
- BCAX (BCAX) notice: 15,000 shares to be sold after option exercise - Stock Titan Mon, 20 Apr 2026 20
- Bicara Therapeutics (BCAX) president exercises options and sells 12,500 shares - Stock Titan Fri, 17 Apr 2026 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
155.60
+88.87%
|
82.39
+106.55%
|
39.89
+5.93%
|
37.66
|
| Research And Development |
|
125.10
+96.63%
|
63.62
+107.79%
|
30.62
-2.22%
|
31.31
|
| Selling General And Administration |
|
30.51
+62.54%
|
18.77
+102.44%
|
9.27
+46.15%
|
6.34
|
| General And Administrative Expense |
|
30.51
+62.54%
|
18.77
+102.44%
|
9.27
+46.15%
|
6.34
|
| Salaries And Wages |
|
20.58
+64.07%
|
12.54
+115.55%
|
5.82
+53.16%
|
3.80
|
| Other Gand A |
|
9.93
+59.45%
|
6.22
-32.86%
|
9.27
+264.47%
|
2.54
|
| Total Expenses |
|
155.60
+88.87%
|
82.39
+106.55%
|
39.89
+5.93%
|
37.66
|
| Operating Income |
|
-155.60
-88.87%
|
-82.39
-106.55%
|
-39.89
-5.93%
|
-37.66
|
| Total Operating Income As Reported |
|
-155.60
-88.87%
|
-82.39
-106.55%
|
-39.89
-5.93%
|
-37.66
|
| EBITDA |
|
-155.50
-88.87%
|
-82.33
-106.50%
|
-39.87
-5.69%
|
-37.72
|
| Normalized EBITDA |
|
-155.50
-88.87%
|
-82.33
-106.50%
|
-39.87
-5.69%
|
-37.72
|
| Reconciled Depreciation |
|
0.10
+87.50%
|
0.06
+194.74%
|
0.02
+90.00%
|
0.01
|
| EBIT |
|
-155.60
-88.87%
|
-82.39
-106.55%
|
-39.89
-5.72%
|
-37.73
|
| Net Income |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Pretax Income |
|
-137.73
-103.12%
|
-67.81
-30.45%
|
-51.98
-37.35%
|
-37.84
|
| Net Non Operating Interest Income Expense |
|
17.87
+22.56%
|
14.58
+1009.67%
|
1.31
+1316.67%
|
-0.11
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
0.11
|
| Net Interest Income |
|
17.87
+22.56%
|
14.58
+1009.67%
|
1.31
+1316.67%
|
-0.11
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
0.11
|
| Interest Income Non Operating |
|
17.87
+22.56%
|
14.58
+1009.67%
|
1.31
+32750.00%
|
0.00
|
| Interest Income |
|
17.87
+22.56%
|
14.58
+1009.67%
|
1.31
+32750.00%
|
0.00
|
| Other Income Expense |
|
—
|
—
|
-13.40
-16656.25%
|
-0.08
|
| Other Non Operating Income Expenses |
|
—
|
—
|
-13.40
-16656.25%
|
-0.08
|
| Tax Provision |
|
0.22
+16.04%
|
0.19
+3640.00%
|
0.01
+400.00%
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Net Income From Continuing And Discontinued Operation |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Net Income Continuous Operations |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Normalized Income |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Net Income Common Stockholders |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Diluted EPS |
|
-2.52
+37.78%
|
-4.05
-164.77%
|
-1.53
+37.59%
|
-2.45
|
| Basic EPS |
|
-2.52
+37.78%
|
-4.05
-164.77%
|
-1.53
+37.59%
|
-2.45
|
| Basic Average Shares |
|
54.68
+225.35%
|
16.81
-50.55%
|
33.98
+120.10%
|
15.44
|
| Diluted Average Shares |
|
54.68
+225.35%
|
16.81
-50.55%
|
33.98
+120.10%
|
15.44
|
| Diluted NI Availto Com Stockholders |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
430.99
-15.49%
|
510.00
+117.96%
|
233.98
+3390.71%
|
6.70
|
| Current Assets |
|
422.05
-16.01%
|
502.53
+117.48%
|
231.07
+4536.30%
|
4.98
|
| Cash Cash Equivalents And Short Term Investments |
|
414.80
-15.30%
|
489.71
+112.51%
|
230.44
+5442.09%
|
4.16
|
| Cash And Cash Equivalents |
|
96.69
-80.26%
|
489.71
+112.51%
|
230.44
+5442.09%
|
4.16
|
| Other Short Term Investments |
|
318.12
|
0.00
|
—
|
—
|
| Other Current Assets |
|
7.25
-43.44%
|
12.82
+1925.59%
|
0.63
-23.37%
|
0.83
|
| Total Non Current Assets |
|
8.94
+19.80%
|
7.46
+156.55%
|
2.91
+69.23%
|
1.72
|
| Net PPE |
|
2.03
+140.36%
|
0.84
+3.68%
|
0.81
+28.14%
|
0.64
|
| Gross PPE |
|
2.03
+140.36%
|
0.84
+3.68%
|
0.81
+28.14%
|
0.64
|
| Other Properties |
|
2.03
+140.36%
|
0.84
+3.68%
|
0.81
+28.14%
|
0.64
|
| Other Non Current Assets |
|
6.91
+4.41%
|
6.62
+216.05%
|
2.09
+93.35%
|
1.08
|
| Total Liabilities Net Minority Interest |
|
29.54
+63.03%
|
18.12
-95.27%
|
382.75
+262.78%
|
105.51
|
| Current Liabilities |
|
28.95
+60.92%
|
17.99
+19.26%
|
15.09
-36.87%
|
23.90
|
| Payables And Accrued Expenses |
|
22.79
+59.38%
|
14.30
+9.51%
|
13.06
-42.53%
|
22.72
|
| Payables |
|
7.79
+72.87%
|
4.51
+41.49%
|
3.19
-37.98%
|
5.14
|
| Accounts Payable |
|
7.79
+72.87%
|
4.51
+41.49%
|
3.19
-37.98%
|
5.14
|
| Current Accrued Expenses |
|
15.00
+53.17%
|
9.79
-0.81%
|
9.87
-43.85%
|
17.58
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.04
+63.51%
|
3.08
+76.98%
|
1.74
+48.13%
|
1.18
|
| Current Debt And Capital Lease Obligation |
|
1.12
+84.02%
|
0.61
+112.98%
|
0.28
|
—
|
| Current Capital Lease Obligation |
|
1.12
+84.02%
|
0.61
+112.98%
|
0.28
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.59
+352.67%
|
0.13
-99.96%
|
367.67
+350.52%
|
81.61
|
| Long Term Debt And Capital Lease Obligation |
|
0.59
+352.67%
|
0.13
-64.78%
|
0.37
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.59
+352.67%
|
0.13
-64.78%
|
0.37
|
0.00
|
| Other Non Current Liabilities |
|
—
|
—
|
0.02
-80.00%
|
0.09
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
367.28
+350.51%
|
81.53
|
| Stockholders Equity |
|
401.45
-18.38%
|
491.88
+430.63%
|
-148.77
-50.57%
|
-98.80
|
| Common Stock Equity |
|
401.45
-18.38%
|
491.88
+430.63%
|
-148.77
-50.57%
|
-98.80
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+250.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+250.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
—
|
| Share Issued |
|
56.60
+3.97%
|
54.44
+5.18%
|
51.76
+0.00%
|
51.76
|
| Ordinary Shares Number |
|
56.60
+3.97%
|
54.44
+5.18%
|
51.76
+0.00%
|
51.76
|
| Additional Paid In Capital |
|
760.17
+6.63%
|
712.88
+16673.74%
|
4.25
+90.50%
|
2.23
|
| Retained Earnings |
|
-358.97
-62.42%
|
-221.02
-44.44%
|
-153.02
-51.45%
|
-101.04
|
| Gains Losses Not Affecting Retained Earnings |
|
0.24
|
0.00
|
—
|
—
|
| Other Equity Adjustments |
|
0.24
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
401.45
-18.38%
|
491.88
+430.63%
|
-148.77
-50.57%
|
-98.80
|
| Total Capitalization |
|
401.45
-18.38%
|
491.88
+430.63%
|
-148.77
-50.57%
|
-98.80
|
| Working Capital |
|
393.10
-18.87%
|
484.54
+124.34%
|
215.99
+1242.07%
|
-18.91
|
| Invested Capital |
|
401.45
-18.38%
|
491.88
+430.63%
|
-148.77
-50.57%
|
-98.80
|
| Total Debt |
|
1.71
+131.71%
|
0.74
+12.33%
|
0.66
|
0.00
|
| Capital Lease Obligations |
|
1.71
+131.71%
|
0.74
+12.33%
|
0.66
|
0.00
|
| Net Tangible Assets |
|
401.45
-18.38%
|
491.88
+430.63%
|
-148.77
-50.57%
|
-98.80
|
| Tangible Book Value |
|
401.45
-18.38%
|
491.88
+430.63%
|
-148.77
-50.57%
|
-98.80
|
| Interest Payable |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-106.83
-42.92%
|
-74.75
-63.83%
|
-45.63
-42.25%
|
-32.08
|
| Cash Flow From Continuing Operating Activities |
|
-106.83
-42.92%
|
-74.75
-63.83%
|
-45.63
-42.25%
|
-32.08
|
| Net Income From Continuing Operations |
|
-137.95
-102.88%
|
-68.00
-30.80%
|
-51.98
-37.36%
|
-37.84
|
| Depreciation Amortization Depletion |
|
0.10
+87.50%
|
0.06
+194.74%
|
0.02
+90.00%
|
0.01
|
| Depreciation |
|
0.10
+87.50%
|
0.06
+194.74%
|
0.02
+90.00%
|
0.01
|
| Depreciation And Amortization |
|
0.10
+87.50%
|
0.06
+194.74%
|
0.02
+90.00%
|
0.01
|
| Other Non Cash Items |
|
0.90
+1262.34%
|
-0.08
-100.57%
|
13.49
|
—
|
| Stock Based Compensation |
|
15.01
+102.87%
|
7.40
+289.52%
|
1.90
+134.44%
|
0.81
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
0.57
|
0.00
|
| Change In Working Capital |
|
14.81
+204.79%
|
-14.13
-46.84%
|
-9.62
-294.46%
|
4.95
|
| Change In Prepaid Assets |
|
5.28
+131.34%
|
-16.85
-1743.54%
|
-0.91
+0.87%
|
-0.92
|
| Change In Payables And Accrued Expense |
|
10.46
+296.66%
|
2.64
+130.44%
|
-8.66
-247.56%
|
5.87
|
| Change In Other Current Liabilities |
|
-0.93
-1250.62%
|
0.08
+272.34%
|
-0.05
|
0.00
|
| Investing Cash Flow |
|
-318.45
-3538266.67%
|
-0.01
+98.46%
|
-0.59
-205.21%
|
-0.19
|
| Cash Flow From Continuing Investing Activities |
|
-318.45
-3538266.67%
|
-0.01
+98.46%
|
-0.59
-205.21%
|
-0.19
|
| Net PPE Purchase And Sale |
|
-0.28
-3011.11%
|
-0.01
+98.46%
|
-0.59
-205.21%
|
-0.19
|
| Purchase Of PPE |
|
-0.28
-294.37%
|
-0.07
+87.88%
|
-0.59
-205.21%
|
-0.19
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.06
|
0.00
|
—
|
| Capital Expenditure |
|
-0.28
-294.37%
|
-0.07
+87.88%
|
-0.59
-205.21%
|
-0.19
|
| Net Investment Purchase And Sale |
|
-318.17
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-318.17
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
32.26
-90.34%
|
334.03
+22.58%
|
272.50
+759.74%
|
31.70
|
| Cash Flow From Continuing Financing Activities |
|
32.26
-90.34%
|
334.03
+22.58%
|
272.50
+759.74%
|
31.70
|
| Net Common Stock Issuance |
|
29.50
-91.13%
|
332.43
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
2.76
+72.26%
|
1.60
+976.51%
|
0.15
-6.88%
|
0.16
|
| Changes In Cash |
|
-393.03
-251.59%
|
259.27
+14.58%
|
226.28
+39590.75%
|
-0.57
|
| Beginning Cash Position |
|
489.71
+112.51%
|
230.44
+5442.09%
|
4.16
-12.11%
|
4.73
|
| End Cash Position |
|
96.69
-80.26%
|
489.71
+112.51%
|
230.44
+5442.09%
|
4.16
|
| Free Cash Flow |
|
-107.11
-43.16%
|
-74.82
-61.90%
|
-46.21
-43.22%
|
-32.27
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Amortization Of Securities |
|
0.30
|
0.00
|
—
|
—
|
| Common Stock Issuance |
|
29.50
-91.13%
|
332.43
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
29.50
-91.13%
|
332.43
+22.06%
|
272.35
+763.63%
|
31.54
|
| Net Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
272.35
+763.63%
|
31.54
|
| Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
272.35
+763.63%
|
31.54
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-22 View
- 42026-04-20 View
- 42026-04-17 View
- 10-K2026-03-30 View
- 8-K2026-03-30 View
- 42026-03-26 View
- 42026-03-24 View
- 42026-03-20 View
- 42026-03-17 View
- 42026-03-11 View
- 42026-03-06 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-05 View
- 42026-03-02 View
- 42026-02-27 View
- 8-K2026-02-26 View
- 8-K2026-02-19 View
- 42026-02-04 View
- 42026-02-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|